Market Overview

UPDATE: BMO Capital Markets Reiterates Outperform Rating, Raises PT on Medtronic on FY3Q13 Revenue

Share:
Related MDT
Medtronic CEO: Covidien Merger Has Accelerated Growth Strategy
Medtronic, Inc.: Medtronic Drug-Coated Balloon for Peripheral Artery Disease Tops Standard Balloon Angioplasty in Landmark
The DGI 'Factual 48' Versus 'The Favored 44' (Seeking Alpha)

In a report published Wednesday, BMO Capital Markets reiterated its Outperform rating on Medtronic (NYSE: MDT), and raised its price target from $50.00 to $52.00.

BMO Capital Markets noted, “Medtronic's FY3Q13 revenue was in line, EPS beat, and management reiterated guidance. In FY3Q13, Medtronic delivered revenue of $4.03B (up 2.8%; up 3.8% ex-fx), in line with the consensus estimate including ICD sales of $654 million that were a bit below the consensus' $668 million (we estimate MDT held share at 44.8% y/y) while other revenue components were either essentially in line or somewhat better than expected (e.g., pacemaker sales were $459 million versus consensus' $448 million). EPS of $0.93 beat our consensus-matching $0.91.”

Medtronic closed on Tuesday at $45.80.

Latest Ratings for MDT

DateFirmActionFromTo
Dec 2014Bank of AmericaMaintainsBuy
Nov 2014WedbushMaintainsNeutral
Nov 2014JefferiesMaintainsBuy

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Price Target Analyst Ratings

 

Related Articles (MDT)

Around the Web, We're Loving...

Get Benzinga's Newsletters